Safety, tolerability, and effect on quality of life of a mixture of amino acids and other small molecules in cancer patients

T. Czömpöly, Zoltán Langmár, Mária Bors, Csilla Zsákai, Mária Géczy, Gyula Kulcsár

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed two clinical studies to evaluate the safety, tolerability, and effect on quality of life of a product containing a mixture of amino acids, vitamins, and other small molecules. In the first one period, open-label, multiple-dose study, the safety and tolerability of a 1-week administration was evaluated in 24 healthy volunteers. In the second one period, open-label, multiple-dose, single-arm study, we investigated the safety, tolerability, and effect on quality of life of a 4-week administration in 50 cancer patients. The safety assessment included the monitoring of adverse events, changes in physical status, and clinical laboratory tests. Changes in quality of life were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version 3.0 (EORTC QLQ-C30). We have found that administration of the investigated product is safe and well tolerated in healthy individuals and in cancer patients. Administration of the product to cancer patients significantly improved their quality of life (EORTC QLQ-C30 global health status score: baseline: 24.17±9.2; end of treatment: 47.08±14.56, p

Original languageEnglish
Pages (from-to)124-134
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Volume29
Issue number3
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

Quality of Life
Safety
Amino Acids
Neoplasms
Organizations
Research
Vitamins
Health Status
Healthy Volunteers
Therapeutics
Surveys and Questionnaires

Keywords

  • amino acids
  • cancer
  • chemotherapy
  • quality of life
  • vitamins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Medicine(all)

Cite this

Safety, tolerability, and effect on quality of life of a mixture of amino acids and other small molecules in cancer patients. / Czömpöly, T.; Langmár, Zoltán; Bors, Mária; Zsákai, Csilla; Géczy, Mária; Kulcsár, Gyula.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 29, No. 3, 01.04.2014, p. 124-134.

Research output: Contribution to journalArticle

Czömpöly, T. ; Langmár, Zoltán ; Bors, Mária ; Zsákai, Csilla ; Géczy, Mária ; Kulcsár, Gyula. / Safety, tolerability, and effect on quality of life of a mixture of amino acids and other small molecules in cancer patients. In: Cancer Biotherapy and Radiopharmaceuticals. 2014 ; Vol. 29, No. 3. pp. 124-134.
@article{b37909ae0fba4a09a5eb9f0ec59ef9d0,
title = "Safety, tolerability, and effect on quality of life of a mixture of amino acids and other small molecules in cancer patients",
abstract = "We performed two clinical studies to evaluate the safety, tolerability, and effect on quality of life of a product containing a mixture of amino acids, vitamins, and other small molecules. In the first one period, open-label, multiple-dose study, the safety and tolerability of a 1-week administration was evaluated in 24 healthy volunteers. In the second one period, open-label, multiple-dose, single-arm study, we investigated the safety, tolerability, and effect on quality of life of a 4-week administration in 50 cancer patients. The safety assessment included the monitoring of adverse events, changes in physical status, and clinical laboratory tests. Changes in quality of life were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version 3.0 (EORTC QLQ-C30). We have found that administration of the investigated product is safe and well tolerated in healthy individuals and in cancer patients. Administration of the product to cancer patients significantly improved their quality of life (EORTC QLQ-C30 global health status score: baseline: 24.17±9.2; end of treatment: 47.08±14.56, p",
keywords = "amino acids, cancer, chemotherapy, quality of life, vitamins",
author = "T. Cz{\"o}mp{\"o}ly and Zolt{\'a}n Langm{\'a}r and M{\'a}ria Bors and Csilla Zs{\'a}kai and M{\'a}ria G{\'e}czy and Gyula Kulcs{\'a}r",
year = "2014",
month = "4",
day = "1",
doi = "10.1089/cbr.2013.1573",
language = "English",
volume = "29",
pages = "124--134",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Safety, tolerability, and effect on quality of life of a mixture of amino acids and other small molecules in cancer patients

AU - Czömpöly, T.

AU - Langmár, Zoltán

AU - Bors, Mária

AU - Zsákai, Csilla

AU - Géczy, Mária

AU - Kulcsár, Gyula

PY - 2014/4/1

Y1 - 2014/4/1

N2 - We performed two clinical studies to evaluate the safety, tolerability, and effect on quality of life of a product containing a mixture of amino acids, vitamins, and other small molecules. In the first one period, open-label, multiple-dose study, the safety and tolerability of a 1-week administration was evaluated in 24 healthy volunteers. In the second one period, open-label, multiple-dose, single-arm study, we investigated the safety, tolerability, and effect on quality of life of a 4-week administration in 50 cancer patients. The safety assessment included the monitoring of adverse events, changes in physical status, and clinical laboratory tests. Changes in quality of life were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version 3.0 (EORTC QLQ-C30). We have found that administration of the investigated product is safe and well tolerated in healthy individuals and in cancer patients. Administration of the product to cancer patients significantly improved their quality of life (EORTC QLQ-C30 global health status score: baseline: 24.17±9.2; end of treatment: 47.08±14.56, p

AB - We performed two clinical studies to evaluate the safety, tolerability, and effect on quality of life of a product containing a mixture of amino acids, vitamins, and other small molecules. In the first one period, open-label, multiple-dose study, the safety and tolerability of a 1-week administration was evaluated in 24 healthy volunteers. In the second one period, open-label, multiple-dose, single-arm study, we investigated the safety, tolerability, and effect on quality of life of a 4-week administration in 50 cancer patients. The safety assessment included the monitoring of adverse events, changes in physical status, and clinical laboratory tests. Changes in quality of life were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version 3.0 (EORTC QLQ-C30). We have found that administration of the investigated product is safe and well tolerated in healthy individuals and in cancer patients. Administration of the product to cancer patients significantly improved their quality of life (EORTC QLQ-C30 global health status score: baseline: 24.17±9.2; end of treatment: 47.08±14.56, p

KW - amino acids

KW - cancer

KW - chemotherapy

KW - quality of life

KW - vitamins

UR - http://www.scopus.com/inward/record.url?scp=84896952637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896952637&partnerID=8YFLogxK

U2 - 10.1089/cbr.2013.1573

DO - 10.1089/cbr.2013.1573

M3 - Article

C2 - 24502241

AN - SCOPUS:84896952637

VL - 29

SP - 124

EP - 134

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -